Shukra Pharmaceuticals Limited (BOM:524632)
India
· Delayed Price · Currency is INR | Market Cap | 6.12B |
| Revenue (ttm) | 333.97M |
| Net Income (ttm) | 81.75M |
| Shares Out | 437.88M |
| EPS (ttm) | 0.19 |
| PE Ratio | 74.68 |
| Forward PE | n/a |
| Dividend | 0.10 (0.75%) |
| Ex-Dividend Date | Sep 23, 2024 |
| Volume | 97,281 |
| Average Volume | 221,660 |
| Open | 13.32 |
| Previous Close | 12.69 |
| Day's Range | 13.32 - 13.32 |
| 52-Week Range | 5.75 - 27.15 |
| Beta | 0.23 |
| RSI | 34.95 |
| Earnings Date | May 26, 2025 |
About Shukra Pharmaceuticals
Shukra Pharmaceuticals Limited develops, manufactures, markets, and exports various drugs and dosage forms in India and internationally. Its product portfolio includes macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti tuberculosis, vitamin products, anti allergics, corticosteroids, hyper and hypoglycemic, and other products, as well as antib... [Read more]
Financial Performance
In 2023, Shukra Pharmaceuticals's revenue was 764.66 million, an increase of 28.53% compared to the previous year's 594.93 million. Earnings were 185.37 million, an increase of 320.68%.
Financial StatementsNews
Shukra Pharmaceuticals shares surge 90% in past one month; Check details
Shukra Pharmaceuticals has witnessed a dramatic surge in its stock price, rising by an impressive 90% in the past month. As of January 24, 2025, the stock closed at 224.60. Performance Breakdown: Shuk...
Shukra Pharmaceuticals shares surge 166% in past one month; Check details
Shukra Pharmaceuticals has witnessed a remarkable surge in its stock price, with shares rising by an astounding 166% over the past month. As of January 10, 2025, the stock closed at ₹184.45, marking a...